# Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer

> **NCT03146377** · PHASE2 · COMPLETED · sponsor: **The University of Hong Kong** · enrollment: 32 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Capecitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT03146377
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2017-05-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03146377

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03146377, "Study of Xeloxiri Regimen for Patients With Refractory Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03146377. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*